The effect of tea consumption on the steroid profile.

Sergi Coll, Xavier Matabosch, Lorena Garrostas, Nuria Monfort, Clara Perez-Maña, Nieves Pizarro, Julián A Mateus, Mohammed Ezzel, Rafael de la Torre, Rosa Ventura

Journal: Drug testing and analysis 2019;10(9):1438-1447

PMID: 29659189

Abstract

Green tea (GT), along with its flavonol epigallocatechin-3-gallate (EGCG), has shown to inhibit the UGT2B17 isoenzyme, which is highly involved in the glucuronidation of testosterone (T) and its metabolites. Since the steroid profile (SP) is composed of urinary concentrations of T and related metabolites excreted in both the free and the glucuronide fractions, GT consumption could alter the SP, leading to misunderstanding in doping controls. The aim of the present work was to study the effect of GT consumption on the SP. This study was performed with 29 male volunteers, which could be classified in 2 arms depending on their T/E values (0.12 ± 0.02, n = 12; 1.64 ± 0.90, n = 17). The clinical protocol was designed to evaluate the effect of GT administration on the SP biomarkers. Participants were asked to consume GT with a high content of EGCG for 7 days (5 GT beverages along the whole day for days 1-6 and 9 GT beverages on day 7, corresponding to 520 and 936 mg/day of EGCG, respectively). Urine samples were collected before and during GT consumption at different time periods. The SP was measured using gas chromatography-mass spectrometry. The excretion rates of the SP metabolites did not change after GT consumption. Moreover, the individual evaluation of the subject's steroidal biological passport resulted in normal sequences. The results obtained show that GT consumption does not distort the establishment of normal ranges of SP parameters. Therefore, GT consumption does not need to be considered a confounding factor in the SP evaluation.

Copyright © 2018 John Wiley & Sons, Ltd.

Address: Catalonian Anti-Doping Laboratory, Doping Control Research Group, IMIM, Hospital del Mar, Barcelona, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; Catalonian Anti-Doping Laboratory, Doping Control Research Group, IMIM, Hospital del Mar, Barcelona, Spain.; Integrated Pharmacology and Neurosciences Systems Research Group, IMIM, Barcelona, Spain.; Autonomous University of Barcelona, Bellaterra, Spain.; Integrated Pharmacology and Neurosciences Systems Research Group, IMIM, Barcelona, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; Integrated Pharmacology and Neurosciences Systems Research Group, IMIM, Barcelona, Spain.; Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto Salud Carlos III, Madrid, Spain.

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.